# Howard I Scher

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 171 papers | 45,860 citations | 13854 67 h-index | 5249 165 g-index |
| 178 all docs | 178 docs citations | 178 times ranked | 39528 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. New England Journal of Medicine, 2012, 367, 1187-1197. | 13.9 | 3,847 |
| 2 | Integrative Genomic Profiling of Human Prostate Cancer. Cancer Cell, 2010, 18, 11-22. | 7.7 | 3,151 |
| 3 | Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206. | 9.4 | 2,702 |
| 4 | Integrative Clinical Genomics of Advanced Prostate Cancer. Cell, 2015, 161, 1215-1228. | 13.5 | 2,660 |
| 5 | Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine, 2017, 23, 703-713. | 15.2 | 2,473 |
| 6 | Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. New England Journal of Medicine, 2014, 371, 424-433. | 13.9 | 2,456 |
| 7 | Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2008, 14, 6302-6309. | 3.2 | 1,975 |
| 8 | Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology, 2008, 26, 1148-1159. | 0.8 | 1,960 |
| 9 | Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. Journal of Clinical Oncology, 2016, 34, 557-565. | 0.8 | 1,746 |
| 10 | Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2014, 15, 700-712. | 5.1 | 1,280 |
| 11 | Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. New England Journal of Medicine, 2016, 375, 443-453. | 13.9 | 1,205 |
| 12 | Organoid Cultures Derived from Patients with Advanced Prostate Cancer. Cell, 2014, 159, 176-187. | 13.5 | 1,184 |
| 13 | Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Journal of Clinical Oncology, 2016, 34, 1402-1418. | 0.8 | 1,089 |
| 14 | Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1â€“2 study. Lancet, The, 2010, 375, 1437-1446. | 6.3 | 972 |
| 15 | Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis. Journal of Clinical Oncology, 2005, 23, 8253-8261. | 0.8 | 932 |
| 16 | Rapid screening for psychologic distress in men with prostate carcinoma. Cancer, 1998, 82, 1904-1908. | 2.0 | 867 |
| 17 | Genomic correlates of clinical outcome in advanced prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11428-11436. | 3.3 | 839 |
| 18 | Long-Term Survival in Metastatic Transitional-Cell Carcinoma and Prognostic Factors Predicting Outcome of Therapy. Journal of Clinical Oncology, 1999, 17, 3173-3181. | 0.8 | 658 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer, 1989, 64, 2448-2458. | 2.0 | 654 |
| 20 | Preliminary Results of M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Transitional Cell Carcinoma of the Urothelium. Journal of Urology, 1985, 133, 403-407. | 0.2 | 630 |
| 21 | The long tail of oncogenic drivers in prostate cancer. Nature Genetics, 2018, 50, 645-651. | 9.4 | 601 |
| 22 | Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncology, The, 2009, 10, 233-239. | 5.1 | 558 |
| 23 | Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. JAMA Oncology, 2016, 2, 1441. | 3.4 | 535 |
| 24 | M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Advanced Transitional Cell Carcinoma of the Urothelium. Journal of Urology, 1988, 139, 461-469. | 0.2 | 517 |
| 25 | Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncology, 2019, 5, 471. | 3.4 | 426 |
| 26 | Phase II Study of Lutetium-177â€“Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2013, 19, 5182-5191. | 3.2 | 370 |
| 27 | Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2015, 33, 1348-1355. | 0.8 | 343 |
| 28 | High-risk prostate cancerâ€”classification and therapy. Nature Reviews Clinical Oncology, 2014, 11, 308-323. | 12.5 | 340 |
| 29 | Quality of life of patients with prostate cancer and their spouses. The value of a data base in clinical care. Cancer, 1994, 73, 2791-2802. | 2.0 | 320 |
| 30 | Tumour lineage shapes BRCA-mediated phenotypes. Nature, 2019, 571, 576-579. | 13.7 | 295 |
| 31 | Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. JCO Precision Oncology, 2017, 2017, 1-16. | 1.5 | 286 |
| 32 | Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology, 2020, 77, 508-547. | 0.9 | 278 |
| 33 | Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. Journal of Clinical Oncology, 2019, 37, 1120-1129. | 0.8 | 267 |
| 34 | Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncology, The, 2012, 13, 1210-1217. | 5.1 | 254 |
| 35 | Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nature Medicine, 1998, 4, 50-57. | 15.2 | 249 |
| 36 | Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocrine-Related Cancer, 2004, 11, 459-476. | 1.6 | 212 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Neoadjuvant M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) Effect on the Primary Bladder Lesion. Journal of Urology, 1988, 139, 470-474. | 0.2 | 211 |
| 38 | Feedback Suppression of PI3KÎ± Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3KÎ². Cancer Cell, 2015, 27, 109-122. | 7.7 | 203 |
| 39 | Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer. JAMA Oncology, 2018, 4, 1179. | 3.4 | 190 |
| 40 | Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. Journal of Clinical Oncology, 2018, 36, 572-580. | 0.8 | 187 |
| 41 | Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model. PLoS ONE, 2015, 10, e0139440. | 1.1 | 181 |
| 42 | A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clinical Cancer Research, 2019, 25, 43-51. | 3.2 | 177 |
| 43 | Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 2018, 4, 1344. | 3.4 | 169 |
| 44 | A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. Clinical Cancer Research, 2015, 21, 5277-5285. | 3.2 | 163 |
| 45 | Outcome of Postchemotherapy Surgery After Treatment With Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients With Unresectable or Metastatic Transitional Cell Carcinoma. Journal of Clinical Oncology, 1999, 17, 2546-2546. | 0.8 | 152 |
| 46 | Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer. European Urology, 2017, 71, 874-882. | 0.9 | 150 |
| 47 | The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression. Cancer Cell, 2019, 36, 139-155.e10. | 7.7 | 131 |
| 48 | HER-2 profiling and targeting in prostate carcinoma. Cancer, 2002, 94, 980-986. | 2.0 | 128 |
| 49 | Prostate Cancer Clinical Trial End Points: â€œRECISTâ€ing a Step Backwards. Clinical Cancer Research, 2005, 11, 5223-5232. | 3.2 | 126 |
| 50 | Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results. Journal of Clinical Oncology, 2015, 33, 1356-1363. | 0.8 | 120 |
| 51 | The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. Clinical Cancer Research, 2016, 22, 1510-1519. | 3.2 | 117 |
| 52 | First-in-Human Imaging with <sup>89</sup>Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake. Journal of Nuclear Medicine, 2016, 57, 1858-1864. | 2.8 | 116 |
| 53 | Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract. Cancer, 2000, 88, 1671-1678. | 2.0 | 112 |
| 54 | Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer. Cancer Research, 2017, 77, 5687-5698. | 0.4 | 112 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer. Clinical Cancer Research, 2020, 26, 3230-3238. | 3.2 | 112 |
| 56 | Circulating Tumor Cells in Prostate Cancer: From Discovery to Clinical Utility. Clinical Chemistry, 2019, 65, 87-99. | 1.5 | 109 |
| 57 | Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. European Urology, 2020, 78, 822-830. | 0.9 | 99 |
| 58 | Positron Emission Tomography/Computed Tomographyâ€“Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 2018, 4, 217. | 3.4 | 93 |
| 59 | Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. JCO Precision Oncology, 2020, 4, 355-366. | 1.5 | 93 |
| 60 | Consensus on molecular imaging and theranostics in prostate cancer. Lancet Oncology, The, 2018, 19, e696-e708. | 5.1 | 90 |
| 61 | Expression of Transforming Growth Factor-Î± and the Epidermal Growth Factor Receptor in Human Prostate Tissues. Journal of Urology, 1994, 152, 2120-2124. | 0.2 | 89 |
| 62 | A Fully Synthetic Globo H Carbohydrate Vaccine Induces a Focused Humoral Response in Prostate Cancer Patients: A Proof of Principle. Angewandte Chemie - International Edition, 1999, 38, 563-566. | 7.2 | 87 |
| 63 | Validation and clinical utility of prostate cancer biomarkers. Nature Reviews Clinical Oncology, 2013, 10, 225-234. | 12.5 | 83 |
| 64 | Identification and characterization of circulating prostate carcinoma cells. Cancer, 2000, 88, 2787-2795. | 2.0 | 82 |
| 65 | Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. Science, 2022, 376, . | 6.0 | 75 |
| 66 | Phase I Evaluation of J591 as a Vascular Targeting Agent in Progressive Solid Tumors. Clinical Cancer Research, 2007, 13, 2707-2713. | 3.2 | 73 |
| 67 | Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics. European Urology, 2020, 78, 671-679. | 0.9 | 72 |
| 68 | The Association Between Measures of Progression and Survival in Castrate-Metastatic Prostate Cancer. Clinical Cancer Research, 2007, 13, 1488-1492. | 3.2 | 67 |
| 69 | Analytic and Clinical Validation of a Prostate Cancerâ€“Enhanced Messenger RNA Detection Assay in Whole Blood as a Prognostic Biomarker for Survival. European Urology, 2014, 65, 1191-1197. | 0.9 | 66 |
| 70 | Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study.. Journal of Clinical Oncology, 2012, 30, LBA1-LBA1. | 0.8 | 66 |
| 71 | Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor: A possible new recombinant granulocyte colony-stimulating factor toxicity. Cancer, 1992, 70, 2699-2702. | 2.0 | 64 |
| 72 | Results of a Phase II Study Using Estramustine Phosphate and Vinblastine in Combination With High-Dose Three-Dimensional Conformal Radiotherapy for Patients With Locally Advanced Prostate Cancer. Journal of Clinical Oncology, 2000, 18, 1936-1941. | 0.8 | 64 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI Research, 2015, 5, 28. | 1.1 | 63 |
| 74 | Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance. Cancer Cell, 2017, 32, 792-806.e7. | 7.7 | 61 |
| 75 | A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer. Investigational New Drugs, 2018, 36, 458-467. | 1.2 | 61 |
| 76 | Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer. European Urology, 2020, 77, 170-177. | 0.9 | 60 |
| 77 | A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer. Urology, 2017, 102, 164-172. | 0.5 | 52 |
| 78 | Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 115-141. | 0.9 | 51 |
| 79 | Neoadjuvant M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Extravesical Urinary Tract Tumors. Journal of Urology, 1988, 139, 475-477. | 0.2 | 48 |
| 80 | Novel strategies and therapeutics for the treatment of prostate carcinoma. Cancer, 2000, 89, 1329-1348. | 2.0 | 48 |
| 81 | Adaptive Clinical Trial Designs for Simultaneous Testing of Matched Diagnostics and Therapeutics. Clinical Cancer Research, 2011, 17, 6634-6640. | 3.2 | 46 |
| 82 | The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population. Clinical Cancer Research, 2017, 23, 1967-1973. | 3.2 | 46 |
| 83 | Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 2018, 4, 694. | 3.4 | 46 |
| 84 | Prostate carcinoma. Cancer, 2003, 97, 758-771. | 2.0 | 45 |
| 85 | Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy. Cancer, 1992, 70, 2870-2878. | 2.0 | 44 |
| 86 | Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint. European Urology, 2019, 75, 929-937. | 0.9 | 41 |
| 87 | Chemotherapy for urothelial tract malignancies: Breaking the deadlock. Journal of Surgical Oncology, 1992, 8, 316-341. | 1.4 | 40 |
| 88 | Sertraline relieves hot flashes secondary to medical castration as treatment of advanced prostate cancer. , 1998, 7, 129-132. | | 40 |
| 89 | Long-term Safety and Antitumor Activity in the Phase 1â€“2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer. European Urology, 2015, 68, 795-801. | 0.9 | 39 |
| 90 | Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial. JAMA Oncology, 2020, 6, e193332. | 3.4 | 39 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 530.e15-530.e21. | 0.8 | 38 |
| 92 | Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using<sup>89</sup>Zr-DFO-MSTP2109A Anti-STEAP1 Antibody. Journal of Nuclear Medicine, 2019, 60, 1517-1523. | 2.8 | 38 |
| 93 | Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. Journal of the National Cancer Institute, 2021, 113, 266-273. | 3.0 | 38 |
| 94 | Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors. Cancer, 1990, 65, 2465-2470. | 2.0 | 37 |
| 95 | Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nature Communications, 2018, 9, 1629. | 5.8 | 37 |
| 96 | Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. Journal of Clinical Oncology, 2021, 39, 2926-2937. | 0.8 | 36 |
| 97 | Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort. European Urology, 2015, 67, 310-318. | 0.9 | 35 |
| 98 | Combined Whole Body and Multiparametric Prostate Magnetic Resonance Imaging as a 1-Step Approach to the Simultaneous Assessment of Local Recurrence and Metastatic Disease after Radical Prostatectomy. Journal of Urology, 2017, 198, 65-70. | 0.2 | 32 |
| 99 | The collection of indirect and nonmedical direct costs (COIN) form. Cancer, 2001, 91, 841-853. | 2.0 | 31 |
| 100 | Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians. Clinical Genitourinary Cancer, 2015, 13, e305-e309. | 0.9 | 30 |
| 101 | Comparison of Magnetic Resonance Imaging-stratified Clinical Pathways and Systematic Transrectal Ultrasound-guided Biopsy Pathway for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials. European Urology Oncology, 2019, 2, 605-616. | 2.6 | 30 |
| 102 | Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2020, 4, 1167-1179. | 1.5 | 28 |
| 103 | Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors. Clinical Cancer Research, 2022, 28, 318-326. | 3.2 | 28 |
| 104 | Inhibition of Circulating Dipeptidyl Peptidase 4 Activity in Patients with Metastatic Prostate Cancer. Molecular and Cellular Proteomics, 2014, 13, 3082-3096. | 2.5 | 27 |
| 105 | Everolimus combined with gefitinib in patients with metastatic castrationâ€resistant prostate cancer: Phase 1/2 results and signaling pathway implications. Cancer, 2015, 121, 3853-3861. | 2.0 | 27 |
| 106 | Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial. Cancer, 1993, 72, 3313-3317. | 2.0 | 26 |
| 107 | Morphology-Predicted Large-Scale Transition Number in Circulating Tumor Cells Identifies a Chromosomal Instability Biomarker Associated with Poor Outcome in Castration-Resistant Prostate Cancer. Cancer Research, 2020, 80, 4892-4903. | 0.4 | 26 |
| 108 | Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. Genome Medicine, 2021, 13, 96. | 3.6 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2020, 18, 171-178.e2. | 0.9 | 25 |
| 110 | Do Patients With AR-V7â€“Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions. European Urology, 2017, 71, 4-6. | 0.9 | 24 |
| 111 | Internalization of secreted antigenâ€“targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis. Science Translational Medicine, 2016, 8, 367ra167. | 5.8 | 23 |
| 112 | Estrogen, progesterone, and androgen-binding sites in renal cell carcinoma. Observations obtained in phase II trial of flutamide. Cancer, 1984, 54, 477-481. | 2.0 | 22 |
| 113 | Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease. Cancer Chemotherapy and Pharmacology, 1986, 18, 24-26. | 1.1 | 21 |
| 114 | Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. Clinical Cancer Research, 2021, 27, 4077-4088. | 3.2 | 21 |
| 115 | Biomarker development in the context of urologic cancers. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 295-301. | 0.8 | 20 |
| 116 | Reproducibility and Repeatability of Semiquantitative <sup>18</sup>F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study. Journal of Nuclear Medicine, 2018, 59, 1516-1523. | 2.8 | 20 |
| 117 | Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with <sup>18</sup>F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study. Journal of Nuclear Medicine, 2021, 62, 1050-1056. | 2.8 | 19 |
| 118 | Sertraline relieves hot flashes secondary to medical castration as treatment of advanced prostate cancer. Psycho-Oncology, 1998, 7, 129-132. | 1.0 | 19 |
| 119 | Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide. JAMA Oncology, 2020, 6, 217. | 3.4 | 18 |
| 120 | Controversies in Treatment of Small Cell Carcinoma of the Lung. Cancer Investigation, 1985, 3, 367-387. | 0.6 | 17 |
| 121 | Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptorâ€“Axis Imaging. Journal of Nuclear Medicine, 2016, 57, 73S-78S. | 2.8 | 16 |
| 122 | Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. Prostate, 2020, 80, 1273-1296. | 1.2 | 16 |
| 123 | A peptidomimetic inhibitor of ras functionality markedly suppresses growth of human prostate tumor xenografts in mice. Prospects for long-term clinical utility. Cancer Chemotherapy and Pharmacology, 2000, 46, 79-83. | 1.1 | 15 |
| 124 | Immune-mediated thrombocytopenia secondary to suramin. Cancer, 1993, 71, 851-854. | 2.0 | 14 |
| 125 | Picking the winners in a sea of plenty. Clinical Cancer Research, 2002, 8, 400-4. | 3.2 | 14 |
| 126 | Optimizing the future: how mathematical models inform treatment schedules for cancer. Trends in Cancer, 2022, 8, 506-516. | 3.8 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. European Journal of Cancer, 2022, 170, 296-304. | 1.3 | 14 |
| 128 | PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates. Clinical Cancer Research, 2021, 27, 2050-2060. | 3.2 | 13 |
| 129 | PTEN Loss with ERG Negative Status is Associated with Lethal Disease after Radical Prostatectomy. Journal of Urology, 2020, 203, 344-350. | 0.2 | 12 |
| 130 | Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide. Journal of Urology, 2022, 207, 1010-1019. | 0.2 | 12 |
| 131 | INTERSTITIAL PNEUMONITIS FOLLOWING BICALUTAMIDE TREATMENT FOR PROSTATE CANCER. Journal of Urology, 1998, 160, 131-131. | 0.2 | 11 |
| 132 | Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503). European Urology Oncology, 2021, 4, 543-552. | 2.6 | 11 |
| 133 | Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. Urology, 2021, 155, 165-171. | 0.5 | 11 |
| 134 | Ipilimumab (IPI) in metastatic castrate-resistant prostate cancer (mCRPC): Results from an open-label, multicenter phase I/II study.. Journal of Clinical Oncology, 2012, 30, 25-25. | 0.8 | 11 |
| 135 | Detectable tumor cells in the blood and bone marrow. , 1998, 83, 394-398. | | 10 |
| 136 | Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 507-516. | 2.0 | 10 |
| 137 | Toward Standardization of Preanalytical Procedures for Cell-Free DNA Profiling. Clinical Chemistry, 2020, 66, 3-5. | 1.5 | 8 |
| 138 | Drug development for noncastrate prostate cancer in a changed therapeutic landscape. Nature Reviews Clinical Oncology, 2018, 15, 168-182. | 12.5 | 7 |
| 139 | Reply to L. Dirix, B. De Laere et al, and A. Sharp et al. Journal of Clinical Oncology, 2019, 37, 2184-2186. | 0.8 | 7 |
| 140 | Effect of Preanalytic Variables on an Automated PTEN Immunohistochemistry Assay for Prostate Cancer. Archives of Pathology and Laboratory Medicine, 2019, 143, 338-348. | 1.2 | 7 |
| 141 | Development of an immunofluorescent AR-V7 circulating tumor cell assay â€“ A blood-based test for men with metastatic prostate cancer. Journal of Circulating Biomarkers, 2020, 9, 13-19. | 0.8 | 7 |
| 142 | The Impact of PIK3R1 Mutations and Insulinâ€“PI3Kâ€“Glycolytic Pathway Regulation in Prostate Cancer. Clinical Cancer Research, 2022, 28, 3603-3617. | 3.2 | 7 |
| 143 | Experimental Studies and Phase II Trial of Bisantrene in Advanced Urothelial Malignancies. Cancer Investigation, 1985, 3, 123-127. | 0.6 | 6 |
| 144 | Spine Pain and Metastatic Prostate Cancer: Defining the Contribution of Nonmalignant Etiologies. JCO Oncology Practice, 2022, 18, e938-e947. | 1.4 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | CHAARTED/GETUG 12â€"docetaxel in non-castrate prostate cancers. Nature Reviews Clinical Oncology, 2015, 12, 687-688. | 12.5 | 4 |
| 146 | Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC). British Journal of Cancer, 2018, 119, 1041-1043. | 2.9 | 4 |
| 147 | Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer. Investigational New Drugs, 2021, 39, 499-508. | 1.2 | 4 |
| 148 | Rapid screening for psychologic distress in men with prostate carcinoma. , 1998, 82, 1904. | | 4 |
| 149 | What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 6-11. | 0.9 | 4 |
| 150 | The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial. Clinical Cancer Research, 2022, 28, 860-869. | 3.2 | 4 |
| 151 | Predictive biomarkers of sensitivity to androgen receptor signaling (ARS) and taxane-based chemotherapy in circulating tumor cells (CTCs) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2015, 33, 147-147. | 0.8 | 3 |
| 152 | Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. European Urology Open Science, 2021, 34, 70-78. | 0.2 | 3 |
| 153 | Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality. Prostate, 2022, , . | 1.2 | 3 |
| 154 | Building on Prostate Cancer Working Group 2 to Change the Paradigm from Palliation to Cure. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e204-e212. | 1.8 | 2 |
| 155 | Impact of clinical versus radiographic progression on clinical outcomes in metastatic castration-resistant prostate cancer. ESMO Open, 2020, 5, e000943. | 2.0 | 2 |
| 156 | Assessment of corticosteroid (CS)-associated adverse events (AEs) with long-term (LT) exposure to low-dose prednisone (P) given with abiraterone acetate (AA) to metastatic castration-resistant prostate cancer (mCRPC) patients (Pts).. Journal of Clinical Oncology, 2015, 33, 169-169. | 0.8 | 2 |
| 157 | Correlation Between Imaging-Based Intermediate Endpoints and Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: Analysis of 28 Randomized Trials Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria in 16,511 Patients. Clinical Genitourinary Cancer, 2022, 20, 69-79. | 0.9 | 2 |
| 158 | Optimal Strategy and Benefit of Pulsed Therapy Depend On Tumor Heterogeneity and Aggressiveness at Time of Treatment Initiation. Molecular Cancer Therapeutics, 2022, 21, 831-843. | 1.9 | 2 |
| 159 | Defining new standards of care for men with prostate cancer. Lancet, The, 2016, 387, 1135-1137. | 6.3 | 1 |
| 160 | Prognostic and Predictive Value of a Breast Cancer Expression Signature in Localized Prostate Cancer. JAMA Oncology, 2017, 3, 1673. | 3.4 | 1 |
| 161 | Identification and characterization of circulating prostate carcinoma cells. , 2000, 88, 2787. | | 1 |
| 162 | The collection of indirect and nonmedical direct costs (COIN) form. Cancer, 2001, 91, 841-853. | 2.0 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | HERâ€2 profiling and targeting in prostate carcinoma. Cancer, 2002, 94, 980-986. | 2.0 | 1 |
| 164 | Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men with Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2022, , . | 0.9 | 1 |
| 165 | Current management of hormone-refractory prostate cancer. Clinical Advances in Hematology and Oncology, 2004, 2, 724-6. | 0.3 | 1 |
| 166 | Intracavitary birdcage resonator: Applications to the human prostate. Journal of Magnetic Resonance Imaging, 1995, 5, 365-368. | 1.9 | 0 |
| 167 | A window into new drug development for urologic oncology. Part II: Bench-to-bedside research improves survival in urologic cancer, and the discovery of better biomarkers can help predict patient response, toxicity, and resistance to therapy. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 269. | 0.8 | 0 |
| 168 | A window into new drug development for urologic oncology. Part I: How bench-to-bedside research can result in approval. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 115. | 0.8 | 0 |
| 169 | Author Reply. Urology, 2017, 102, 172. | 0.5 | 0 |
| 170 | Reply to C. Ren et al. Journal of Clinical Oncology, 2018, 36, 2354-2356. | 0.8 | 0 |
| 171 | Improving the Nuclear-Localized Androgen Receptor Splice Variant 7 Testâ€"In Reply. JAMA Oncology, 2019, 5, 434. | 3.4 | 0 |